If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?
This is a randomised controlled trial on 34 patients undergoing routine elective surgery at the Princess Anne Hospital, Southampton. The study will take place from September 2018 to January 2019 and involve preoxygenating all participants for three minutes using the Optiflow™ device. During this time, participants will be instructed to either read aloud a standardised text or to breathe through their nose with a closed mouth. At the end of 3 minutes, the primary outcome, ETO2, will be measured and recorded.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
34
45l.min oxygen
University Hospital Southampton
Southampton, Hants, United Kingdom
End Tidal Oxygen Fraction
Oxygen fraction in first expired breath post preoxygenation
Time frame: At the end of 3 minutes preoxygenation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.